JP2004521129A - フォン・ヴィレブランド病の処理方法 - Google Patents
フォン・ヴィレブランド病の処理方法 Download PDFInfo
- Publication number
- JP2004521129A JP2004521129A JP2002567345A JP2002567345A JP2004521129A JP 2004521129 A JP2004521129 A JP 2004521129A JP 2002567345 A JP2002567345 A JP 2002567345A JP 2002567345 A JP2002567345 A JP 2002567345A JP 2004521129 A JP2004521129 A JP 2004521129A
- Authority
- JP
- Japan
- Prior art keywords
- factor xiii
- disease
- vwf
- von willebrand
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000027276 Von Willebrand disease Diseases 0.000 title claims abstract description 22
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 title claims abstract description 22
- 238000011282 treatment Methods 0.000 title description 7
- 108010071289 Factor XIII Proteins 0.000 claims abstract description 27
- 229940012444 factor xiii Drugs 0.000 claims abstract description 26
- 108010054218 Factor VIII Proteins 0.000 claims abstract description 17
- 102000001690 Factor VIII Human genes 0.000 claims abstract description 17
- 229960000301 factor viii Drugs 0.000 claims abstract description 17
- 239000012141 concentrate Substances 0.000 claims abstract description 8
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 claims abstract description 7
- 229960004281 desmopressin Drugs 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 208000032843 Hemorrhage Diseases 0.000 claims description 6
- 208000034158 bleeding Diseases 0.000 claims description 6
- 230000000740 bleeding effect Effects 0.000 claims description 6
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 claims 2
- NFLWUMRGJYTJIN-PNIOQBSNSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-PNIOQBSNSA-N 0.000 abstract description 9
- 108010047303 von Willebrand Factor Proteins 0.000 description 32
- 102100036537 von Willebrand factor Human genes 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 210000002889 endothelial cell Anatomy 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229960002845 desmopressin acetate Drugs 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 2
- 102000023159 Platelet Glycoprotein GPIb-IX Complex Human genes 0.000 description 2
- 108010045766 Platelet Glycoprotein GPIb-IX Complex Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940005769 koate Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010061298 Mucosal haemorrhage Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27046001P | 2001-02-21 | 2001-02-21 | |
| PCT/US2002/003742 WO2002067980A1 (en) | 2001-02-21 | 2002-02-07 | Method for treating von willebrand's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004521129A true JP2004521129A (ja) | 2004-07-15 |
| JP2004521129A5 JP2004521129A5 (https=) | 2008-11-20 |
Family
ID=23031409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002567345A Pending JP2004521129A (ja) | 2001-02-21 | 2002-02-07 | フォン・ヴィレブランド病の処理方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6979445B2 (https=) |
| EP (1) | EP1379271A1 (https=) |
| JP (1) | JP2004521129A (https=) |
| CA (1) | CA2438761A1 (https=) |
| WO (1) | WO2002067980A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101010333B (zh) | 2004-08-27 | 2013-08-14 | 诺和诺德医疗保健公司 | 从生物材料中纯化凝血因子xⅲ多肽 |
| EP2297330A4 (en) * | 2008-06-04 | 2012-03-14 | Bayer Healthcare Llc | FVII MUTINES FOR THE TREATMENT OF MORBUS WILLEBRAND |
| US10172911B2 (en) | 2013-10-01 | 2019-01-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of modulating erythropoiesis with arginine vasopressin receptor 1B molecules |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004505016A (ja) * | 2000-05-10 | 2004-02-19 | ノボ ノルディスク アクティーゼルスカブ | 第ＶＩＩａ因子及び第ＸＩＩＩ因子を含んで成る医薬組成物 |
-
2002
- 2002-02-07 EP EP02714852A patent/EP1379271A1/en not_active Withdrawn
- 2002-02-07 US US10/468,113 patent/US6979445B2/en not_active Expired - Fee Related
- 2002-02-07 JP JP2002567345A patent/JP2004521129A/ja active Pending
- 2002-02-07 CA CA002438761A patent/CA2438761A1/en not_active Abandoned
- 2002-02-07 WO PCT/US2002/003742 patent/WO2002067980A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US6979445B2 (en) | 2005-12-27 |
| WO2002067980A1 (en) | 2002-09-06 |
| US20040067230A1 (en) | 2004-04-08 |
| EP1379271A1 (en) | 2004-01-14 |
| CA2438761A1 (en) | 2002-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mannucci | Treatment of von Willebrand's disease | |
| EP2310043B2 (en) | Factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes | |
| EP1935429A1 (en) | Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates | |
| US20240417739A1 (en) | Compositions and methods for treatment of bleeding disorders | |
| Robertson et al. | von Willebrand disease | |
| Mannucci | Treatment of von Willebrand disease | |
| Rodeghiero et al. | Treatment of von Willebrand disease | |
| US20170119857A1 (en) | Method of Administering Porcine B-Domainless fVIII | |
| ALEDORT | Treatment of von Willebrand's disease | |
| Rick | Diagnosis and management of von Willebrand's syndrome | |
| Mannucci et al. | Management of inherited von Willebrand disease | |
| Lee | Von Willebrand disease, hemophilia A and B, and other factor deficiencies | |
| US6979445B2 (en) | Method for treating von willebrand's disease | |
| JPH05507926A (ja) | 抗凝血剤 | |
| Wilde et al. | von Willebrand disease and its management in oral and maxillofacial surgery | |
| Mannucci | Treatment of von Willebrand's disease | |
| US20090036361A1 (en) | Use of Blood Coagulation Factor XIII for Treating Hemophilia A | |
| US20220233650A1 (en) | Recombinant factor viii-fc for treating hemophilia and low bone mineral density | |
| US7429566B2 (en) | Method for treating Hemophilia B | |
| Baronciani | The molecular basis of von W illebrand disease | |
| EP1351706B1 (en) | Factor xiii in combination with factor ix for treating hemophilia b | |
| Lillicrap | von Willebrand disease | |
| Abshire | von Willebrand Disease | |
| WO2002036155A1 (en) | Use of blood coagulation factor xiii for treating haemophilia a | |
| US8377887B1 (en) | Methods of reducing hypoxic stress in a mammal by administering soluble P-selectin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050114 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080325 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080619 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080626 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080925 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20080925 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081104 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090123 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090130 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090602 |